Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0B65S3
Mon, 18.09.2023
PAION AG
First Berlin Equity Research has published a research update on PAION AG
(ISIN: DE000A0B65S3). Analyst Simon Scholes reiterated his BUY rating and
decreased the price target from EUR 38.00 to EUR 11.00.
Abstract:
PAION's lead product remimazolam was first approved in January 2020 in
Japan in the indication general anesthesia (GA). It has since [ … ]
Mon, 03.04.2023
PAION AG
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam f [ … ]
Mon, 03.04.2023
PAION AG
PAION receives European Commission approval of remimazolam for the Induction and maintenance of general anesthesia in adults
Aachen (Germany), 03 April 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Commission (EC) has approved remimazolam f [ … ]
Fri, 31.03.2023
PAION AG
PAION AG implements resolved capital reduction
Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordin [ … ]
Fri, 31.03.2023
PAION AG
PAION AG implements resolved capital reduction
Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordin [ … ]
Thu, 30.03.2023
PAION AG
PAION AG reports on fiscal year 2022
Combined revenues of EUR 33.2 million
Cash and cash equivalents of EUR 10.6 million as of 31 December 2022
Positive EBITDA of EUR 1.5 million
Capital reduction carried out in the first quarter of 2023
Initiatives to expand commercial distribution continued, including the successful expansion of partner ne [ … ]
Thu, 30.03.2023
PAION AG
PAION AG reports on fiscal year 2022
Combined revenues of EUR 33.2 million
Cash and cash equivalents of EUR 10.6 million as of 31 December 2022
Positive EBITDA of EUR 1.5 million
Capital reduction carried out in the first quarter of 2023
Initiatives to expand commercial distribution continued, including the successful expansion of partner ne [ … ]
Thu, 16.03.2023
PAION AG
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels
PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II
Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65 [ … ]
Thu, 16.03.2023
PAION AG
PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS
Sponsored Symposium & poster presentation about angiotensin II at 42nd ISICEM 2023, 21-24 March 2023, Brussels
PAION to present new data from a post hoc analysis of the ATHOS-3 study with angiotensin II
Aachen (Germany), 16 March 2023 – PAION AG (ISIN DE000A0B65 [ … ]
Fri, 27.01.2023
PAION AG
PAION receives positive CHMP opinion recommending approval of remimazolam for the induction and maintenance of general anesthesia in adults
Aachen (Germany), 27 January 2023 – The specialty pharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces that today the European Medicines Agency’s Committ [ … ]